scholarly journals Mitral Valve Repair for Mitral Valve Regurgitation with Papillary Muscle Displacement and Posterior Leaflet Prolapse

2017 ◽  
Vol 07 (03) ◽  
pp. 39-45
Author(s):  
Masaho Okada ◽  
Hirotaka Watanuki ◽  
Kayo Sugiyama ◽  
Yasuhiro Futamura ◽  
Katsuhiko Matsuyama
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Papillary Muscle ◽  
Mitral Valve Regurgitation ◽  
Posterior Leaflet ◽  
Valve Regurgitation ◽  
Valve Repair ◽  
Leaflet Prolapse

scholarly journals Sequential Venous Percutaneous Transluminal Angioplasty and Balloon Dilatation of the Interatrial Septum during Percutaneous Edge-to-Edge Mitral Valve Repair

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Rezo Jorbenadze ◽  
Johannes Patzelt ◽  
Meinrad Gawaz ◽  
Peter Seizer ◽  
Harald F. Langer
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Percutaneous Transluminal Angioplasty ◽  
Balloon Dilatation ◽  
Mitral Valve Regurgitation ◽  
Interatrial Septum ◽  
Transluminal Angioplasty ◽  
Valve Regurgitation ◽  
Valve Repair ◽  
Percutaneous Transluminal

Percutaneous edge-to-edge mitral valve repair (PMVR) is widely used for selected, high-risk patients with severe mitral valve regurgitation (MR). This report describes a case of 81-year-old woman presenting with severe and highly symptomatic mitral valve regurgitation (MR) caused by a flail of the posterior mitral valve leaflet (PML). PMVR turned out to be challenging in this patient because of a stenosis and tortuosity of both iliac veins as well as sclerosis of the interatrial septum, precluding the vascular and left atrial access by standard methods, respectively. We managed to achieve atrial access by venous percutaneous transluminal angioplasty (PTA) and balloon dilatation of the interatrial septum. Subsequently, we could advance the MitraClip® system to the left atrium, and deployment of the clip in the central segment of the mitral valve leaflets (A2/P2) resulted in a significant reduction of MR.

scholarly journals Similar long-term results of mitral valve repair for anterior compared with posterior leaflet prolapse

2006 ◽  
Vol 131 (2) ◽  
pp. 364-370 ◽  
Author(s):  
Michele De Bonis ◽  
Roberto Lorusso ◽  
Elisabetta Lapenna ◽  
Samer Kassem ◽  
Giuseppe De Cicco ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Long Term Results ◽  
Posterior Leaflet ◽  
Valve Repair ◽  
Leaflet Prolapse

Operative Results of Mitral Valve Repair and Replacement in Chronic Ischaemic Mitral Valve Regurgitation

2018 ◽  
Vol 27 ◽  
pp. S514
Author(s):  
Damian Gimpel ◽  
Levi Bassin ◽  
Peter Grant ◽  
Zakir Akhunji ◽  
Beatrix Weiss ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Mitral Valve Regurgitation ◽  
Valve Regurgitation ◽  
Valve Repair ◽  
Operative Results

scholarly journals Site-Level Variability in 30-Day Patient Outcomes After Transcatheter Mitral Valve Repair in the United States

2020 ◽  
Vol 13 (12) ◽  
Author(s):  
Ali O. Malik ◽  
Adnan K. Chhatriwalla ◽  
John Saxon ◽  
Vittal Hejjaji ◽  
Amanda Stebbins ◽  
...  
Keyword(s):  
Health Status ◽  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Odds Ratio ◽  
Mitral Valve Regurgitation ◽  
Valve Regurgitation ◽  
Valve Repair ◽  
Transcatheter Mitral Valve Repair ◽  
Baseline Health ◽  
Baseline Health Status

Background: Clinical trials have demonstrated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients with mitral valve regurgitation. Real-world site-level variability in health status outcomes for TMVr, and factors associated with this variability, are unknown. Methods: All patients undergoing TMVr procedure with MitraClip between November 2013 and March 2019 in the Transcatheter Valve Therapy Registry were included. Health status was measured at baseline and 30 days with the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary (OS) score. Site-level variability in 30-day change in KCCQ-OS was examined by calculating the median odds ratio from a hierarchical logistic regression model, with ≥20-point improvement as the dependent variable. To define the extent to which patient characteristics, procedural characteristics (residual mitral valve regurgitation, periprocedural bleeding), site volume, and patients’ baseline health status accounted for variability in outcomes, the proportion of variability ( R 2 ) explained by sequentially adding these variables to the model was quantified. Results: Across 339 sites, 12 415 patients (mean age 79.0±9.5 years, 46.1%. females, 89.5% White) completed baseline and 30-day health status assessments. Mean KCCQ-OS score was 43.0±24.4 at baseline and 67.0±24.9 at 30-day follow-up. Across sites, the proportion of patients achieving a ≥20-point improvement in KCCQ-OS ranged from 12.5% to 100% and the adjusted median odds ratio was 1.58 (95% CI, 1.46–1.69). The greatest contribution to the variability in health status outcomes was from patients’ baseline KCCQ-OS score ( R 2 =25%) with <1% of the variability explained by patient and procedural characteristics, and annual site volume. Conclusions: There is moderate variation across sites in their patients’ achievement of health status benefits from TMVr, with patient’s baseline health status accounting for the largest proportion of this variation. This underscores the importance of patient selection in supporting more consistent health status benefit from TMVr.

Sign in / Sign up

Export Citation Format

Share Document